349 related articles for article (PubMed ID: 28622097)
1. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
[TBL] [Abstract][Full Text] [Related]
2. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
3. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
4. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
5. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
[TBL] [Abstract][Full Text] [Related]
6. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
8. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
Ogawa K; Matsumoto T; Esaki M; Torisu T; Iida M
J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
[TBL] [Abstract][Full Text] [Related]
9. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
[TBL] [Abstract][Full Text] [Related]
10. A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease.
Li L; Chen R; Zhang Y; Zhou G; Chen B; Zeng Z; Chen M; Zhang S
Front Immunol; 2021; 12():646673. PubMed ID: 34367126
[TBL] [Abstract][Full Text] [Related]
11. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
[TBL] [Abstract][Full Text] [Related]
12. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
Suzuki Y; Matsui T; Ito H; Ashida T; Nakamura S; Motoya S; Matsumoto T; Sato N; Ozaki K; Watanabe M; Hibi T
Inflamm Bowel Dis; 2015 Sep; 21(9):2114-22. PubMed ID: 26218144
[TBL] [Abstract][Full Text] [Related]
13. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
[TBL] [Abstract][Full Text] [Related]
14. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
[TBL] [Abstract][Full Text] [Related]
15. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease.
Salvador-Martín S; López-Cauce B; Nuñez O; Laserna-Mendieta EJ; García MI; Lobato E; Abarca-Zabalía J; Sanjurjo-Saez M; Lucendo AJ; Marín-Jiménez I; Menchén LA; López-Fernández LA
Pharmacol Res; 2019 Nov; 149():104478. PubMed ID: 31605784
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
Reinisch W; Wang Y; Oddens BJ; Link R
Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
[TBL] [Abstract][Full Text] [Related]
18. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
Bertani L; Fornai M; Fornili M; Antonioli L; Benvenuti L; Tapete G; Baiano Svizzero G; Ceccarelli L; Mumolo MG; Baglietto L; de Bortoli N; Bellini M; Marchi S; Costa F; Blandizzi C
Aliment Pharmacol Ther; 2020 Jul; 52(2):284-291. PubMed ID: 32506635
[TBL] [Abstract][Full Text] [Related]
19. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.
Davidov Y; Ungar B; Bar-Yoseph H; Carter D; Haj-Natour O; Yavzori M; Chowers Y; Eliakim R; Ben-Horin S; Kopylov U
J Crohns Colitis; 2017 May; 11(5):549-555. PubMed ID: 28453755
[TBL] [Abstract][Full Text] [Related]
20. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
